Norges Bank
ADVM

Norges Bank’s Adverum Biotechnologies ADVM Stock Holding History

Norges Bank’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,399
Closed -$694K – 2131
2020
Q4 		$694K Sell
6,399
-15,780
-71% -$1.95M ﹤0.01% 2059
2020
Q3 		$2.28M Buy
+22,179
New +$3.32M ﹤0.01% 1955
2020
Q1 		– Sell
-17,487
Closed -$2.01M – 2049
2019
Q4 		$2.01M Sell
17,487
-7,099
-29% -$626K ﹤0.01% 1984
2019
Q3 		$1.34M Buy
24,586
+14,685
+148% +$1.66M ﹤0.01% 2019
2019
Q2 		$1.18M Buy
+9,901
New +$819K ﹤0.01% 2026
2017
Q1 		– Sell
-16,727
Closed -$485K – 2140
2016
Q4 		$485K Hold
16,727
– – ﹤0.01% 2117
2016
Q3 		$657K Hold
16,727
– – ﹤0.01% 2089
2016
Q2 		$529K Hold
16,727
– – ﹤0.01% 2119
2016
Q1 		$865K Hold
16,727
– – ﹤0.01% 2079
2015
Q4 		$1.59M Hold
16,727
– – ﹤0.01% 2059
2015
Q3 		$1.38M Buy
16,727
+13,995
+512% +$1.79M ﹤0.01% 2077
2015
Q2 		$444K Hold
2,732
– – ﹤0.01% 2193
2015
Q1 		$1.11M Buy
+2,732
New +$1.15M ﹤0.01% 2148

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank's ADVM Position: Q1 2021 in Review

Norges Bank sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 6,399 shares — an estimated $694K sold.

Norges Bank first reported a position in ADVM in Q1 2015 and held it in 13 quarters. The position peaked at $2.28M in Q3 2020. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Norges Bank reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Norges Bank sold 6,399 Adverum Biotechnologies shares in Q1 2021, an estimated $694K.
  • Norges Bank first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 13 quarters.
  • Norges Bank's Adverum Biotechnologies position peaked at $2.28M in Q3 2020.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.